CPT code 87482 represents a molecular laboratory assay that quantifies infection with Candida species using a nucleic acid probe technique. This diagnostic test provides species-level molecular detection and quantification, which can inform clinical management of suspected invasive or mucocutaneous Candida infections. Nationally, molecular diagnostics for fungal pathogens play a growing role in timely, accurate diagnosis and can affect antimicrobial stewardship and resource allocation.

Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find information about the clinical context for using a nucleic acid probe to detect Candida, typical settings where the test is performed, and how the code is identified in billing systems. The publication also covers payer coverage patterns, common modifiers and administrative considerations, and comparisons to related laboratory procedures when data are available.

This summary provides a concise reference for coding staff, laboratory managers, and policy analysts seeking to understand what CPT code 87482 denotes, where the service is typically delivered, and the payer landscape commonly involved with molecular fungal diagnostics. Data not available in the input are noted where applicable.